ANZCTR search results

This study aims to examine the effects of a brief mindfulness meditation induction and a mindfulness meditation training intervention on neural correlates of attention (as measured by event-related potential components and EEG spectral activity) and measures of anxiety in young adults with high levels of anxiety and minimal meditation experience. A secondary aim is to identify individual characteristics related to attention changes, engagement/adherence to the intervention, and psychological outcomes (i.e., anxiety, other measures of wellbeing). Improvements in attention processes and reductions in anxiety are expected.

Comprehension of prognostic information might be affected by how the information is presented to patients or their caregivers. Subsequently, this might affect what health management decisions they make and further affect their health wellbeing. This is a four-parallel arm online randomised controlled trial. Two separate groups of adult Australians will be recruited using an online provider (Dynata) to participate in one of two trials. Trial A: Acute middle ear infection (Acute medical condition) and trial B: Tennis elbow (chronic medical condition). Participants of each trial will be randomly assigned to one of four groups: text only, bar graph, pictograph, and line graph. The four interventions in each trial will convey the same prognostic information but will be presented in four different visual formats. Comprehension of the presented information will be measured and its association to health literacy, numeracy, and educational level. As secondary outcomes, we will measure participants’ intentions towards which treatment option they would choose in each condition. Additionally, we will measure participants’ satisfaction with the presentation they were allocated to as well as their preferred presentation to be used in future communication.

This project aims to understand how a parenting intervention influences emotional brain function in adolescent females at risk for depressive disorders. Participants will be randomly assigned to the intervention or the waitlist control group. Parents of adolescents in the intervention group will receive the TINT parenting program, which has shown to be effective in increasing parental emotional socialisation and decreasing adolescents' internalising symptoms. We hypothesise that adolescents whose parents are in the intervention group will show greater improvements in brain function and connectivity in the neural circuits underlying emotion regulation (i.e., greater reductions in amygdala activity and greater increases in prefrontal-amygdala connectivity) at 6-month follow-up compared to adolescents whose parents are in the waitlist control group.

The purpose of this study is to determine whether a nanoparticle cannabis-based medicine (NanaBis™) is effective in reducing metastatic bone pain in patients with cancer. Who is it for? You may be eligible for this study if you are aged between 18-75 years old, have been diagnosed with any cancer that has metastasised to bone, and are experiencing bone pain. Study details Participants will be randomised using a computer software program to receive either the NanaBis™ spray and placebo oxycodone tablets for breakthrough pain, a placebo spray and oxycodone tablets or a placebo spray and placebo tablets. Participants will self-administer the spray into their mouth up to 2-7 times every 4 hours unless asleep, and the tablet up to twice per day as needed. All participants will answer a number of questionnaires before the study starts and throughout the study. These questionnaires are answered weekly during the visits to the study site, except for the Numerical Pain Rating Scale which is completed twice daily as part of the participants medication diary. All questionnaires are also completed at the end of the 6-week period. Participants will also have the option to continue the treatment for a further 12 weeks after the study is complete. It is hoped that this study may demonstrate that NanaBis™ is safe, tolerable, and effective at reducing metastatic bone pain in patients with cancer.

The gold standard of OSA management is CPAP (Continuous Positive Airway Pressure). Adherence to CPAP remains the main barrier to effective therapy due to the cumbersome nature of the mask interfaces and their propensity to leak. We aim to assess whether custom made CPAP masks, which are not common or readily available, will improve patients’ adherence to treatment and therefore improve treatment outcomes.

This is a randomised controlled study of women who require an induction of labour, to determine if excess, or inappropriate infusions of fluid given via a vein (intravenous route) is having an effect upon the duration of labour. For this study, women who require an induction of labour will be randomised to receive intravenous fluid at a rate of 40 ml/hr or 250 ml/hr. The duration of labour (in minutes), will be calculated from the commencement of an intravenous infusion of a medication to start labour (a hormone called oxytocin), until the birth of the baby.

The Paediatric Facioscapulohumeral muscular dystrophy (FSHD) Longitudinal Outcome Study (iFSHD-LOS) is designed to observe and record the natural disease progression of children and young adults aged 0-21 years diagnosed with FSHD (type 1 and type 2) through the collection of longitudinal data recording their medical, physical and psychological functioning. The study aims to: 1.Contribute to standards of care guidelines for children and young adults world-wide with FSHD. 2.Contribute to outcome measure and biomarker development to enhance clinical trial readiness. 3.Establish the cognitive and psychological profile of children and young adults with FSHD. 4.Develop a biobank of patient iPSCs to model disease and identify novel treatments in the future.

High sensitivity troponin assays have led to increased numbers of patients presented to the emergency department (ED) for suspected acute coronary syndrome (ACS) now having detectable troponin levels. For those with low level troponin elevated, there is limited evidence to guide care. It is suggested that individuals in this zone, have a higher risk of poor outcomes and the risk versus benefit of invasive coronary angiography (ICA) is less clear as the likelihood of an evolving heart attack is lower. Computed tomography coronary angiography (CTCA), being a less invasive alternate approach, may provide useful information to inform subsequent care to these lower risk patients. This randomised clinical trial aims to investigate CTCA vs. ICA in suspected ACS with low level troponin elevations in the ED. Outcomes will be assessed at 30 days and 12 months. A pilot study will be performed initially until greater funding can be sourced.

The prevalence of childhood obesity and overweight is a critical health issue in Queensland. A recent report indicated that 26% of children in Queensland are overweight (19%) or obese (7%). Although the causes of childhood obesity are complex, the intake of energy-dense, nutrient-poor food is a key contributor to obesity in Australian schoolchildren. Parental influence, role modeling, and the home environment are the strongest determinants of healthy eating in children, particularly for the younger age groups. As key role models and decision-makers regarding their child’s food intake, parents have a critical role to play in childhood dietary practices. This is especially true of parents of children aged 2-6 years as this is a formative period for the development of a child’s lifestyle habits and behaviour and a critical period for parental support seeking. Low-intensity programs that are embedded within the principles of positive parenting have shown promising results in improving health behaviours in children. Therefore, it is essential to develop interventions that target specific parenting contexts, such as parenting practices related to dietary intake. Here, we intend to evaluate the efficacy of a novel web-based program, ‘Healthy Habits for Life Triple P’, which is based on the Triple P-Positive parenting Program system of family behavioural intervention.

The ASCEND clinical trial aims to measure the effect of adding CEND-1 (a new cancer drug) or a placebo, to standard chemotherapy (gemcitabine and nab-paclitaxel) in patients who have untreated metastatic pancreatic cancer. Who is it for? You may be eligible for this study if you are aged 18 or older, you have been diagnosed with metastatic pancreatic ductal adenocarcinoma, and you have adequate liver and kidney function determined by blood tests. Study details Participants who choose to enrol in this study will be randomly allocated by chance (with 2/3 patients randomly assigned to the CEND-1 treatment) to receive either CEND1 in addition to the standard chemotherapy (gemcitabine and nab-paclitaxel), or a placebo in addition to the standard chemotherapy. Both CEND1 and the placebo will be administered by an intravenous infusion over a 28-day treatment cycle. Participants will continue to receive these treatments every 28 days until the cancer is seen to have progressed, or until treatment side effects become intolerable. Participants will undergo continuous monitoring for side effects throughout treatment, as well as completing questionnaires, blood tests and CT scans every 8 weeks for up to 18 months after starting the treatment. It is hoped that this trial will provide information on whether CEND1 is safe and effective for the treatment of metastatic pancreatic cancer.